EVO ICL

What is EVO ICL?

EVO-ICL stands for EVO Implantable Collamer® Lens (ICL) is an advanced vision correction procedure that offers an alternative to LASIK for individuals with myopia (nearsightedness) and astigmatism who desire glasses independence.

Unlike LASIK, which permanently reshapes the cornea, EVO-ICL involves implanting a biocompatible lens inside the eye between the iris and the natural lens.The “EVO” refers to the latest generation of the ICL, which is designed to offer improved performance and safety.

Benefits of EVO ICL:

Works with the eye’s natural anatomy for high-definition vision
Does not remove corneal tissue
Provides superior night vision
No risk of dry eye
Removable and replaceable if needed

EVO-ICL has been used globally for over 30 years, with more than 2 million lenses implanted worldwide. The U.S. FDA approved the latest version in 2022, marking a milestone in vision correction advancements.

Am I a Good Candidate?

EVO-ICL is recommended for patients who:

-Are between 21 and 45 years old
– Have stable vision for at least one year
– Have moderate to severe myopia (-3.00D to -20.00D) with or without astigmatism (up to +4.00D)

Can I get both eyes done at the same time?

Yes! The procedure is commonly performed on both eyes during the same visit.

The EVO-ICL Surgery Process

Easy 20-30 Minute Surgical Procedure

Pre-Op Eye Exam

Eye Drops Administered

Small Opening

Lens Insertion and Positioning

Post Op & Check-up

Recovery

Most patients experience vision improvement within one day

Will the surgery hurt?

No, the procedure is painless due to local anesthesia, though mild discomfort may occur during recovery.

How Does EVO-ICL Compare to LASIK?

Cost and Financing for EVO ICL

The cost of an EVO ICL procedure can vary depending on your personalized treatment plan. Many EVO ICL patients
look forward to spending less in the long run with the EVO ICL compared to the continued costs of contact lenses and glasses. Ask about financing options and payment plans that may be available for your EVO ICL procedure.

What is Dropless Surgery?

Traditionally, patients use prescription eye drops (antibiotics, anti-inflammatory, and steroid drops) after surgery. With the dropless technique, a long-acting antibiotic and steroid are injected into the eye during surgery, eliminating the need for post-op drops.

Benefits of Dropless Surgery

Convenience – No need for multiple post-op eye drops.

Lower Cost – Reduces expenses on medications.

Reduced Infection Risk – Ensures consistent medication delivery.

Preoperative Assessment

In-Office Evaluation: At our Rotunda office, we conduct comprehensive eye measurements and advanced imaging studies to assess your ocular health. During this visit, we will also discuss candidacy, the surgical process in detail, including procedural expectations.

Recovery & Aftercare

Day 1: Most patients notice vision improvement.
First Few Days: Minor glare or halos may occur but usually resolve.
Follow-ups: Scheduled visits to ensure optimal healing.

Are There Any Risks?

EVO-ICL is a safe and well-established procedure, but potential risks include:

Infection: Extremely rare (1 in 3,000). Proper post-op care minimizes this risk.
Glare/Halos: Usually temporary and resolves naturally. Rare cases may require an in-office procedure or repositioning of the lens.

“With Visian ICL my eyes are now clearer than they have ever been at night.”

– Phil, Biologist

“It’s as if my eyesight was never any issue; it’s just simply better.”

– Puno, App Designer

Interested in EVO-ICL?

Schedule a consultation with Dr. Maria S. Romero at Precision Eye Care today!

Achieve clear, sharp vision with EVO-ICL – a life-changing alternative to glasses and contacts!

Request a Free Consultation:

Important Safety Information for EVO ICL

The EVO Visian ICL lens is intended to correct/reduce nearsightedness between -3.0 D up to -20.0 D and treat astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO Visian ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO Visian ICL corrects for distance vision, it does not eliminate the need for reading glasses, you may require them at some point, even if you have never worn them before. Since implantation of the EVO Visian ICL is a surgical procedure, before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery. Complications, although rare, may include need for additional surgical procedures, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts. You should NOT have EVO Visian ICL surgery if your doctor determines that 1) the shape of your eye is not appropriate, 2) you do not meet the minimum endothelial cell density for your age at the time of implantation, 3) you have moderate to severe glaucoma, 4) your vision is not stable; or 5) if you are pregnant or nursing.

For additional information with potential benefits, risks and complications please visit DiscoverICL.com

Martínez-Plaza E, López-Miguel A, López-de la Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125. 2 Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration clinical trial. Clinical Ophthalmology. 2022;16:1541-53. 3 Parkhurst G, Psolka M, Kezirian G. Phakic intraocular lens implantation in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481 4 Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017 Jul 3;11:1253-1263. 5 Naves J.S, Carracedo G, Cacho-Babillo I, Diadenosine nucleotid measurements as dry-eye score in patients after LASIK and ICL surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012. 6 Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016;10:1209-1215. 7 Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clin Ophthalmol. 2018;12:2427-2438.

(410) 377-2422